Free Trial

Kumaraguru Raja Analyst Performance

Analyst at Brookline Capital Management

Kumaraguru Raja is a stock analyst at Brookline Capital Management in the medical sector, covering 13 publicly traded companies. Over the past year, Kumaraguru Raja has issued 2 stock ratings, including and buy recommendations. While full access to Kumaraguru Raja's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kumaraguru Raja's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 8 Years
Buy Recommendations
100.00% 19 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%19 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
13 companies

Kumaraguru Raja, an analyst at Brookline Capital Management, currently covers 13 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
13 companies
100.0%

Kumaraguru Raja of Brookline Capital Management specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
30.8%
MED - DRUGS
4 companies
30.8%
PHARMACEUTICAL PREPARATIONS
3 companies
23.1%
MED PRODUCTS
1 company
7.7%
BIOTECHNOLOGY
1 company
7.7%

Kumaraguru Raja's Ratings History at Brookline Capital Management

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
8/28/2025Set Price Target$4.28$8.00
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
8/12/2025Upgrade$0.29$3.00Buy